Abstract
The invention in this patent describes novel 5H-imidazo[1,5-b][1,2,4]triazole compounds, including radiolabeled derivatives, designed to target alpha-synuclein (α-syn). These compounds demonstrate potential as positron emission tomography (PET) radioligands for diagnosing α-syn-associated brain diseases, including Parkinson's disease.